|
KMID : 0893420210220050075
|
|
Journal of Veterinary Science
2021 Volume.22 No. 5 p.75 ~ p.75
|
|
|
Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
|
|
Song Doo-Won
Ro Woong-Bin
Park Hee-Myung
|
|
|
Abstract
|
|
|
Background: Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have important roles in tumor evasion of the immune system.
Objectives: This study aimed to assess the diagnostic utility of circulating PD-1 and PD-L1 levels in healthy dogs and dogs with tumors.
Methods: Circulating PD-1 and PD-L1 levels in the serum of 71 dogs with tumors were compared with those of 52 healthy dogs by performing enzyme-linked immunosorbent assay (ELISA).
Results: The ELISA results revealed higher circulating PD-1 and PD-L1 levels in dogs with tumors (2.9 [2.2?3.7] ng/mL; median [IQR] and 2.4 [1.4?4.4] ng/mL, respectively) than in healthy dogs (2.4 [1.9?3.0] ng/mL; p = 0.012 and 1.4 [0.9?2.1] ng/mL; p < 0.001, respectively). Especially, there was a significant difference in circulating PD-1 levels between healthy dogs and dogs with malignant epithelial tumors (2.4 [1.9?3.0] ng/mL and 3.1 [2.6?4.4] ng/mL, respectively; p < 0.01). In addition, there was a significant difference in circulating PD-L1 levels between healthy dogs and dogs with lymphomas (1.4 [0.9?2.1] ng/mL and 2.7 [1.6?5.8] ng/mL, respectively; p < 0.001).
Conclusion: This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
|
|
|
KEYWORD
|
|
|
Dog, tumor, biomarker, programmed cell death protein, ligand
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|